[McPharmNet Home | Journal Club | McPharmNews | McPharmNet Faculty | Education | Sponsors | Sites to Visit]

[Paper of the Month | Posted Comments | How To Post A New Paper | Archive of Past Papers]

Neurotoxicity Induces Cleavage of 
p35 to p25 by Calpain

Ming-sum Lee* Young T. Kwon* Mingwei Li', Jummin Peng', Robert M. Friedlander' & Li Huel Tsai'
*Howard Hughes Medical Institute and Department of Pathology, Harvard Medical School, 200 Longwood Avenue, Boston, Massachusetts 02115, USA; 'Neuroapoptasis Laboratory, Neurosurgical Service, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Nature (2000) Vol. 405: 360-364

Presenter: Dr. Venugopalan D. Nair

Background
Cyclin-dependent kinase 5 (cdk5) and its neuron-specific activator p35 are required for neurite outgrowth and cortical lamination. Proteolytic cleavage of p35 produces p25, which accumulates in the brains of patients with Alzheimer's disease. Conversion of p35 to p25 causes prolonged activation and mis-localization of cdk5. Consequently, the p25/cdk5 kinase hyper-phosphorylates tau, disrupts the cytoskeleton and promotes the death (apoptosis) of primary neurons. 
Summary
In cultured primary cortical neurons, excitotoxins, hypoxic stress and calcium influx induce the production of p25. In fresh brain lysates, addition of calcium can stimulate cleavage of p35 to p25. Specific inhibitors of calpain, a calcium-dependent cysteine protease, effectively inhibit the calcium-induced cleavage of p35. In vitro, calpain directly cleaves p35 to release a fragment with relative molecular mass 25,000. The sequence of the calpain cleavage product corresponds precisely to that of p25. Application of the amyloid ß-peptide Aß(1-42)induces the conversion of p35 to p25 in primary cortical neurons. Furthermore, inhibition of cdk5 or calpain activity reduces cell death in Aß treated cortical neurons. These observations indicate that cleavage of p35 to p25 by calpain may be involved in the pathogenesis of Alzheimer's disease.
Rationale
The open reading frame of p35 does not contain introns, so alternative splicing cannot account for the generation of p25. Internal initiation of translation of p35 messenger RNA is also unlikely to produce p25 because there is no internal methionine near the beginning of the p25 sequence. Proteolytic cleavage is, therefore, the most likely mechanism for conversion of p35 to p25.
Experimental Findings
  • The authors sought to determine whether p25 could be produced in vivo under certain experimental conditions. They found that 4 h of focal ischaemia, induced by middle cerebral artery occlusion in mice, produced p25 in the ipsilateral cortex but not in the control contralateral cortex.
  • Treatment with hydrogen peroxide stimulate cleavage of p35 to p25 in primary neurons. Other insults such as treatment with the excitatory amino-acid glutamate also caused the production of p25 in cortical neurons at high concentrations of glutamate. An increase in intracellular calcium levels, caused by the calcium ionophore ionomycin, stimulated efficient conversion of p35 to p25. These results indicate that neurotoxicity induces cleavage of p35 to p25 and suggest a role for calcium in this process.
  • To identify the protease that cleaves p35 to p25, they used the proteolytic cleavage event. In fresh mouse brain lysates,1 mM Ca2+ efficiently stimulates the cleavage of p35. The cleavage product is likely to be p25, as it has a relative molecular mass of 25K. The p25 was specifically recognized by the p35 carboxy-terminal- specific antibody, but not by the p35 amino-terminal-specific antibody.
  • To identify the protease activated by calcium, protease inhibitors with different specificities for their effectiveness in inhibiting the calcium-stimulated p35 conversion. Calpeptin and calpain inhibitor II, which inhibit the calcium- dependent cysteine protease calpain, completely inhibited p35 cleavage, whereas the general cysteine protease inhibitor leupeptin partially inhibited p35 cleavage. The lack of effect of the cdk5 inhibitor roscovitine indicates that cdk5 activity may not be necessary for cleavage to occur. 
  • To investigate further whether calpain cleaves p35 in brain lysates, fractionats of mouse brain lysates were examined whether the p35 cleavage activity co-segregated with calpain activity. Incubation of the glycerol gradient fractions with either purified p35 showed that both p35 cleavage activity and calpain activity completely co-segregated in the same fractions. Depletion of m-calpain from brain lysates using an m-calpain-specific antibody significantly reduced the Ca2+-induced cleavage of p35. further indicating that conversion of p35 to p25 may lie downstream of calpain activation.
  • Incubation of purified m-calpain and µ-calpain with purified p35, cleaved p35 to a 25K fragment.
  • In primary cortical neurons, H2O2 or ionomycin did not stimulate conversion of p35 to p25. Similarly, removing calcium with either EGTA or BAPTA-AM also prevented conversion of p35. These results indicate that calcium is necessary for conversion of p35. The addition of calpeptin, which inhibits calpain activity in neurons also inhibited the cleavage of endogenous p35 to p25 caused by H2O2. Similarly, conversion of p35 to p25 induced by ionomycin was completely reversed by increasing concentrations of calpeptin. Together, these experiments indicate that activation of calpain by neurotoxic processes through calcium influx is both necessary and sufficient for conversion of p35 to p25 in cortical neurons.
  • p25 is found to accumulate in brains of Alzheimer's disease patients but not in normal brains.The Aß peptides are primary constituents of the amyloid plaques found in the brains of patients with Alzheimer's disease. They have been shown to aggregate and cause neuronal deaths. Treatment of primary cortical neurons with 20 µM Aß (1-42) peptide resulted in conversion of p35 to p25. These results indicate that, in Alzheimer's disease, the abundant amyloid plaques in the brain can cause calpain activation and conversion of p35 to p25.
Possible Mechanisms
The tight regulation of p35 allows cdk5 to be activated in a temporally and spatially specific manner. In contrast, p25 causes mislocalization and constitutive activation of cdk5. The cleavage of p35 to p25 by calpain represents a new regulatory mechanism whereby proteolytic cleavage deregulates a protein kinase. By cleaving p35, calpain does not destroy cdk5 activity; rather, it alters the properties of cdk5 such that the p25/cdk5 kinase causes collapse of the cytoskeleton and cell death. Thus, whereas p35/cdk5 activity is necessary for proper development and other functions of the mature nervous system, p25/cdk5 activity is detrimental to neurons.
Significnace
Altered calcium homeostasis is a convergence point of various aetiological factors relevant to the pathogenesis of Alzheimer's disease. In particular, loss of calcium homeostasis has been implicated in causing tau hyper- phosphorylation and neuronal apoptosis. This study, showing cleavage of p35 to p25 by calpain, suggests one mechanism by which calcium can activate a tau-phosphorylating kinase. Activated m-calpain and µ-calpain are both abnormally upregulated in the brains of patients with Alzheimer's disease. In addition, active m-calpain accumulates in neurofibrillary tangles in Alzheimer's disease brains.
The amyloid hypothesis proposes that the Aß peptides, perhaps acting with other influences such as excitotoxins, free radicals and oxidative stress, cause an increased or unregulated entry of calcium into affected cells, which ultimately leads to the activation of a tau-phosphorylating kinase. The findings in this paper indicate that cdk5 may be one of the kinases 'activated' by amyloid-ß peptide through calpain-mediated conversion of p35 to p25. Given the potentially deleterious role of cdk5 in Alzheimer's disease, the calpain-mediated p35 cleavage pathway may serve as a target for pharmacological intervention. 

Acknowledgement: I thank Mrs. Manju Venugopal for the preparation of this document.

[McPharmNet Home | Journal Club | McPharmNews | McPharmNet Faculty | Education | Sponsors | Sites to Visit]
[Paper of the Month | Posted Comments | How To Post A New Paper | Archive of Past Papers]

McPharmNet - Molecular Pharmacology at McMaster / mcpharm@fhs.csu.mcmaster.ca /

Last revised July 2, 2000